Pay in 4 interest-free payments of $5.58 Learn more
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24
MTII activates melanocortin receptors (MC1R through MC5R) with substantially higher potency than endogenous -MSH, making it a pharmacological research tool for studying the melanocortin system
Key contraindications include: Personal or family history of medullary thyroid cancer (MTC) or multiple endocrine neoplasia type 2 (MEN2) : Animal studies show a link to thyroid tumors, so these drugs are avoided to prevent potential risks
HCC-specific data included alpha fetoprotein, maximum viable tumor diameter + number of viable tumors on imaging, receipt of locoregional therapy (LRT), and explant pathology data used to calculate RETREAT score
With retatrutide, you risk losing the additional metabolic benefit that makes it worth the added complexity and cost
Biochemistry 46 , 90419049 (2007)
